


PAEDIATRIC INVASIVE MENINGOCOCCAL DISEASE IN AUCKLAND, 2004-2017

C. Burton, M. Broom, E. Best, S. Johansson,
M. Hansen, H. Heffernan, S. Briggs, R. Webb



NEISSERIA MENINGITIDIS

Gram negative diplococcus

Serogroups based on polysaccharide capsule – A, B, C, W, Y

Human reservoir – nasopharynx


Transmission through respiratory droplets or direct contact with nasopharyngeal secretions

Meningococcus invades epithelium and enters bloodstream – sepsis, meningitis



MENZB™ & THE NEW ZEALAND EPIDEMIC

Figure 12.1: Notified cases of meningococcal disease, 1970–2015



Source: ESR



AIMS & METHODS


To describe the Auckland experience of paediatric invasive meningococcal disease

Assessment of outcomes related to penicillin-susceptible vs reduced penicillin susceptibility

Institute of Environmental Science and Research (ESR) notifications for all positive meningococcal cultures from sterile sites

Between 2004 and 2017 in children <15 years from the Auckland region

Clinical notes and National Immunisation Register data reviewed




RESULTS

168



cases of invasive meningococcal disease in children <15 years in the greater Auckland region between 2004 and 2017

- Estimated $\frac{2}{3}$ of Auckland paediatric IMD, $\frac{1}{4}$ of New Zealand paediatric IMD


Meningococcal Cases by Year






SEROGROUPS




GROUP B:4 STRAIN



DEMOGRAPHICS




Meningococcal Cases by Age




CLINICAL PRESENTATIONS


168 cases



CLINICAL PRESENTATIONS




had an initial temperature $\geq 38^{\circ}\text{C}$ or $< 36^{\circ}\text{C}$



presented with a rash




petechiae




blanching




purpuric




mixed



of those with meningitis presented with meningism



presented with septic arthritis



with arthralgia

INTENSIVE CARE

22%
(37)

were admitted to an intensive care unit

14%
(24)

required inotropic support

11%
(18)


required mechanical ventilation

2%
(4)


required renal replacement therapy




OUTCOMES



Cure



Sequelae




Deaths


	Cure	Sequelae	Death	Total	p-value
Meningitis	22 (85%)	4 (15%)	0 (0%)	26	0.92
Bacteraemia	66 (85%)	9 (13%)	3 (4%)	78	
Meningitis with Bacteraemia	46 (82%)	7 (13%)	3 (5%)	56	
Septic Arthritis	2 (100%)	0 (0%)	0 (0%)	2	
Total	136	20	6	162	
Admitted to ICU	22 (61%)	10 (28%)	4 (11%)	36	<0.001
Not admitted to ICU	114 (90%)	10 (8%)	2 (2%)	126	




SEQUELAE




Sensorineural hearing loss




required hearing aids




referred for cochlear implants



Skin or extremity complications



Neurological sequelae




Chronic renal impairment



PENICILLIN MIC

Proportion of isolates with penicillin MIC >0.06mg/L



No statistically significant difference in outcomes in those with penicillin-susceptible isolates compared to those with reduced penicillin susceptibility



MENZB™

101/168 were eligible to receive MeNZB™

90% completed MeNZB™

MeNZB™ received before admission:

- Completed course: 31 (19%)
- Partially-completed: 29 (18%)
- Not received MeNZB™: 104 (63%)



MENZB™ & PRESENTATIONS



B:4 Strain Presentation	MeNZB™ Schedule			p-value
	No MeNZB Received	Partially Complete	Complete	
Meningitis	2 (4%)	6 (30%)	1 (6%)	0.06
Bacteraemia	28 (61%)	8 (40%)	7 (44%)	
Meningitis with Bacteraemia	15 (33%)	6 (30%)	7 (44%)	
Isolated septic arthritis	1 (2%)	0 (0%)	1 (6%)	
Total	46	20	16	
Required ICU	12 (26%)	5 (25%)	2 (13%)	0.53



MENZB™ & OUTCOMES



B:4 Strain Outcome	MeNZB™ Schedule			P-value
	No MeNZB Received	Partially Complete	Complete	
Cure	37 (80%)	16 (80%)	14 (88%)	0.75
Sequelae	5 (11%)	2 (10%)	2 (13%)	
Death	2 (4%)	2 (10%)	0 (0%)	
Total	44	20	16	



CONCLUSIONS

Invasive meningococcal disease remains a significant cause of morbidity and mortality in Auckland

Lower case fatality rate (3.7%) from Auckland paediatric cohort

Burden of sequelae (12%) – hearing loss (9%)

In those who developed B:4 disease, prior administration of MeNZB™ did not appear to impact on morbidity and mortality

Meningococcal disease remains a public health priority in New Zealand



Thank you!

